Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2011-07-18 Regulatory Filings
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing the start of shipment of the Fluvirin seasonal influenza vaccine for the 2011-2012 season. It includes detailed product information, safety information, and forward-looking statements. There are no financial statements, audit opinions, or detailed financial data presented. The document is primarily a corporate announcement about product shipment and public health information, not a financial report or regulatory filing of financial results. It is not an Annual Report, Interim Report, Earnings Release, or any other financial report type. It is also not a report publication announcement or certification. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-07-18 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis International AG, submitted to the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The content of the document is an investor relations release announcing Phase III clinical trial results for the drug Afinitor (everolimus). It includes detailed clinical trial data, study design, patient outcomes, and regulatory approval status. The document is not a full annual or quarterly financial report, nor is it an earnings release or management discussion. It is a regulatory filing providing material information to investors about clinical trial results and drug development progress. Given the nature of the document as a Form 6-K and its content, the appropriate classification is Regulatory Filings (RNS).
2011-07-11 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis International AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing regulatory approval in Japan for a new drug, Onbrez, including clinical data and market information. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is primarily an announcement of a regulatory approval and product launch, not a financial report or earnings release. It is not a certification or attestation. The length is about 11,858 characters, which is substantial but the content is clearly a press release. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2011-07-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing FDA approval of a new drug, Arcapta Neohaler, including clinical trial results and product launch plans. There are no financial statements, detailed financial performance data, or comprehensive management discussion and analysis. The document is an announcement of a regulatory approval and product update rather than a financial report or earnings release. It is not a full annual or interim report, nor is it a call transcript or management change announcement. Given the nature of the content and the form type (6-K), this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (11,898 characters) is substantial but the content is a press release rather than a financial report. Therefore, the classification is RNS with high confidence.
2011-07-05 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing clinical trial results for a drug (NVA237) and related forward-looking statements. There are no financial statements, detailed financial analysis, or comprehensive report data included. The document is about a clinical study result announcement rather than a financial report or regulatory filing with substantive financial data. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any other detailed financial or governance report. The document is longer than 5,000 characters but is essentially a press release filed as a Form 6-K. Form 6-K filings typically serve as regulatory filings to disclose material information to the SEC for foreign issuers. Given the nature of the content and the filing form, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-07-05 English
Regulatory Filings 2011
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from Novartis AG to the US Securities and Exchange Commission (SEC) regarding the Form 20-F for the fiscal year ended December 31, 2010. It includes responses to SEC comments on disclosures, research and development expenditures, impairment of assets, and valuation methods related to acquisitions. The Form 20-F is an annual report filed by foreign private issuers, equivalent to the US 10-K annual report. The content is focused on clarifications and additional disclosures related to the annual report filing, indicating this is part of the annual reporting process rather than a standalone audit report or a simple announcement. The document length is substantial (15,000 characters), and it contains substantive financial and operational information. Therefore, the document should be classified as an Annual Report (10-K equivalent) filing or closely related correspondence to it. Given the nature of the document as a letter responding to SEC comments on the annual report, it is best classified under Regulatory Filings (RNS) because it is correspondence and not the actual annual report itself. However, since the letter is detailed and integral to the annual report process, and the Form 20-F is the annual report for foreign issuers, the best fit is Regulatory Filings (RNS) as it is a regulatory correspondence related to the annual report, not the report itself.
2011-06-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.